Integrated Filing (Financial) for the quarter and financial year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenotech Laboratories has filed audited standalone financial results for FY25 along with related party transaction details. Revenue from operations grew modestly to Rs 3,897.57 lakhs (vs Rs 3,676.15 lakhs in FY24), while total income stood at Rs 4,459.57 lakhs. However, profit after tax fell sharply to Rs 561.29 lakhs from Rs 829.87 lakhs, dragged by higher employee costs (up ~31%) and a steep rise in tax expense (Rs 507.90 lakhs vs Rs 284.27 lakhs). An exceptional gain of Rs 192.32 lakhs came from reversal of provisions on settled EPCG export licenses. EPS declined to Rs 0.92 from Rs 1.36. Operating cash flow remained healthy at Rs 948.84 lakhs, and the company continues to carry virtually no debt. Auditor PKF Sridhar & Santhanam LLP issued an unmodified (clean) opinion.
Shareholders should note the sharp drop in annual profit despite stable revenue, mainly due to higher staff costs and taxes, which compresses margins. The clean audit opinion and debt-free balance sheet are positives, while the significant related-party transactions with majority owner Sun Pharma warrant close attention.